Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN

Caxton Associates LLP bought a new stake in Arvinas, Inc. (NASDAQ:ARVN) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 298,062 shares of the company’s stock, valued at approximately $2,194,000. Caxton Associates LLP owned 0.41% of Arvinas at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Arvinas by 18.4% in the first quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company’s stock valued at $58,703,000 after acquiring an additional 1,299,639 shares during the period. Deutsche Bank AG lifted its holdings in shares of Arvinas by 5.3% in the 1st quarter. Deutsche Bank AG now owns 228,633 shares of the company’s stock worth $1,605,000 after purchasing an additional 11,413 shares in the last quarter. Invesco Ltd. grew its position in Arvinas by 119.4% in the 1st quarter. Invesco Ltd. now owns 81,747 shares of the company’s stock valued at $574,000 after purchasing an additional 44,493 shares during the period. Nuveen LLC acquired a new stake in Arvinas in the 1st quarter valued at $1,170,000. Finally, Russell Investments Group Ltd. increased its stake in Arvinas by 444.8% during the 1st quarter. Russell Investments Group Ltd. now owns 41,549 shares of the company’s stock valued at $292,000 after purchasing an additional 33,922 shares in the last quarter. 95.19% of the stock is owned by institutional investors.

Insider Activity at Arvinas

In related news, Director Briggs Morrison purchased 30,000 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The shares were bought at an average cost of $7.57 per share, with a total value of $227,100.00. Following the acquisition, the director owned 76,021 shares of the company’s stock, valued at $575,478.97. This represents a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.73% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ARVN has been the subject of a number of analyst reports. The Goldman Sachs Group reiterated a “sell” rating and set a $6.00 price objective (down from $8.00) on shares of Arvinas in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research report on Tuesday, December 9th. Wells Fargo & Company decreased their price objective on Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Barclays increased their price objective on Arvinas from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Bank of America cut Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 target price on the stock. in a research report on Wednesday, September 24th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Arvinas presently has an average rating of “Hold” and a consensus target price of $16.39.

Arvinas Stock Up 0.1%

Shares of NASDAQ ARVN opened at $12.58 on Monday. The company has a market capitalization of $807.89 million, a PE ratio of -15.53 and a beta of 2.44. The stock’s 50 day moving average price is $10.80 and its 200-day moving average price is $8.74. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $21.00.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The company had revenue of $41.90 million during the quarter, compared to the consensus estimate of $29.36 million. During the same period last year, the business posted ($0.68) earnings per share. Arvinas’s revenue was down 59.1% on a year-over-year basis. As a group, research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Arvinas announced that its Board of Directors has approved a stock repurchase program on Wednesday, September 17th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 17.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.